Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Natalie Delrocco"'
Autor:
Corey B. Simon, Mark D. Bishop, Margaret R. Wallace, Roland Staud, Natalie DelRocco, Samuel S. Wu, Yunfeng Dai, Paul A. Borsa, Warren H. Greenfield, Roger B. Fillingim, Steven Z. George
Publikováno v:
The Journal of Pain.
Publikováno v:
Statistics in Biosciences. 15:1-30
Biomedical studies, such as clinical trials, often require the comparison of measurements from two correlated tests in which each unit of observation is associated with a binary outcome of interest via relative risk. The associated confidence interva
Autor:
Natalie Delrocco, Mignon L. Loh, Michael Borowitz, Karen R Rabin, Patrick A Zweidler-McKay, Kelly W Maloney, Leonard A. Mattano, Eric C Larsen, Anne L Angiolillo, Reuven J Schore, Michael J. Burke, Wanda L Salzer, Brent L. Wood, Andrew J Carroll, Nyla A. Heerema, Shalini C Reshmi, Julie M Gastier-Foster, Richard C Harvey, I-Ming L Chen, Kathryn G Roberts, Charles G. Mullighan, Cheryl L Willman, Naomi J Winick, William L. Carroll, Stephen P. Hunger, Elizabeth A. Raetz, Meenakshi Devidas, John Kairalla
Publikováno v:
Blood. 138:2382-2382
Contemporary risk stratification algorithms commonly use threshold-defined categories of clinically relevant risk factors. The Children's Oncology Group (COG) uses National Cancer Institute (NCI) risk group (RG), cytogenetics, and early response to t
Autor:
Eric Larsen, Brent L. Wood, Reuven J. Schore, Shalini C. Reshmi, Kathryn G. Roberts, Nyla A. Heerema, Leonard A. Mattano, Michael J. Borowitz, Wanda L. Salzer, Richard C. Harvey, Elizabeth A. Raetz, John A. Kairalla, Stephen P. Hunger, Cheryl L. Willman, Julie M. Gastier-Foster, Andrew J. Carroll, Meenakshi Devidas, Charles G. Mullighan, Michael J. Burke, Patrick A. Zweidler-McKay, Kelly W. Maloney, Natalie DelRocco, Karen R. Rabin, Anne L. Angiolillo, Mignon L. Loh, Naomi J. Winick, William L. Carroll, I-Ming L. Chen
Publikováno v:
Blood. 136:39-40
Current risk stratification for COG ALL patients (pts) relies on National Cancer Institute (NCI) risk group (RG) at diagnosis, somatic genetics, and early response to therapy as measured by specific thresholds of minimal residual disease (MRD) using